Summary: Exercise is a proven antidepressant, yet depression often saps the energy and motivation needed to move. A new paper from the University of Ottawa explores a futuristic approach: exercise mimetics — pharmacological agents designed to make skeletal muscle behave as if it has just completed a sustained workout. These compounds could activate the muscle-brain axis and release the same muscle-derived signals (the myosecretome) that reduce inflammation and support brain health, potentially providing treatment options for people who cannot exercise due to physical or psychological barriers.
Researchers argue that targeted exercise mimetics could reproduce key molecular signals produced during endurance activity, prompting release of myokines and neurotrophic factors that benefit mood and cognition. The proposal is framed as a complement to, not a replacement for, conventional exercise and existing depression treatments.
Key Facts
- Muscle as a secretory organ: Skeletal muscle comprises roughly 40–50% of adult body mass and functions as an endocrine-like organ that communicates with the brain by releasing myokines and other signaling molecules.
- Exercise mimetics: These agents are designed to engage specific molecular pathways in muscle to reproduce the biochemical effects of prolonged endurance exercise without physical exertion.
- Muscle-brain axis: Activation of muscle-derived signaling can elevate neurotrophic factors and lower systemic inflammation, mechanisms linked to improved mood and resilience.
- Target populations: The intended beneficiaries include people who cannot exercise easily—elderly individuals, stroke survivors, or patients with severe depression—rather than healthy people seeking to avoid physical activity.
- Call to action: The authors recommend advancing preclinical work into carefully designed human trials to evaluate safety, efficacy, and how these agents might integrate with psychotherapy and pharmacotherapy.
Source: University of Ottawa
Many people recognize the mental clarity and mood improvement that follow a run or a workout. Population studies and clinical trials confirm that regular physical activity reduces the risk of depression and that, for some people with non-severe depressive symptoms, exercise can be as effective as conventional antidepressant medication or psychotherapy.
Yet depression itself presents obstacles to exercise: persistent low energy, impaired motivation, anhedonia, and other functional limitations frequently prevent patients from initiating or sustaining physical activity. These barriers are even greater for those with mobility impairments or neurological injury. The new University of Ottawa perspective suggests exercise mimetics as a therapeutic strategy to bypass those barriers and deliver exercise-associated biochemical benefits directly to the nervous system.
From gym conversation to research proposal
The concept originated in informal conversations between medical trainees and faculty at a university gym. Dr. Nicholas Fabiano, lead author and psychiatry resident, recounts speaking with Professor Bernard Jasmin about muscle’s role beyond movement. Those discussions evolved into a collaborative scientific effort that examines how muscle-derived signaling might be emulated with drugs to support brain health.
“The idea spans from bench press to bedside,” says Dr. Fabiano, noting that while exercise has clear antidepressant effects, many who would benefit most cannot perform regular physical activity. The team asked whether it is possible to transfer the relevant biological signals to patients by other means.
Hacking the muscle-brain axis
Professor Jasmin describes skeletal muscle as a major therapeutic platform: when active, muscles release a complex set of signaling molecules — the myosecretome — that modulate inflammation and promote neurotrophic support. The paper proposes that pharmacological activation of specific pathways could mimic these effects, potentially improving mood and reducing depressive symptoms without requiring strenuous exercise.
Clinical perspective and limitations
The authors emphasize that exercise mimetics are not intended to replace the physical, cardiovascular, and social benefits of real exercise for the general population. Instead, they present a possible medical tool for those who cannot safely or practically engage in sufficient physical activity. The team urges rigorous human trials to assess whether mimetics can safely reproduce key biochemical effects of exercise and whether they improve clinical outcomes when combined with standard therapies.
Key Questions Answered:
A: At the molecular level, there is evidence that the signals muscles send to the brain are identifiable and potentially targetable. Exercise mimetics aim to activate those pathways, but translating that into safe, effective medicines for people requires further research.
A: The primary beneficiaries would be high-risk groups unable to exercise: elderly individuals with mobility limitations, stroke survivors, and people with severe depression whose symptoms make physical activity impractical.
A: A mimetic could reproduce some of the chemical signals linked to improved mood and cognitive clarity, but it cannot replace the full range of social, cardiovascular, and experiential benefits associated with actual exercise. It is intended as a medical adjunct, not a lifestyle shortcut.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was provided by staff to clarify clinical implications and limitations.
About this psychopharmacology and depression research news
Author: Bernard Rizk
Source: University of Ottawa
Contact: Bernard Rizk – University of Ottawa
Image: The image is credited to Neuroscience News
Original Research: Open access. “Exercise mimetics as unexplored therapeutics for treating depression” by Nicholas Fabiano, Jess G. Fiedorowicz, Aymeric Ravel-Chapuis & Bernard J. Jasmin. Published in Molecular Psychiatry. DOI: 10.1038/s41380-026-03499-2
Abstract
Exercise mimetics as unexplored therapeutics for treating depression
Depressive disorders rank among the leading causes of global disability. Epidemiological evidence shows that even achieving half the recommended level of physical activity is associated with a substantially lower risk of developing depression. Clinical studies also indicate that exercise can be as effective as first-line treatments for some people with non-severe depression.
However, people with depression often face multiple barriers to exercising, including persistent fatigue, low motivation, loss of pleasure, socioeconomic constraints, comorbid conditions, and time pressures. These challenges contribute to poorer adherence and higher dropout rates in exercise interventions compared with medication despite the known side effects of antidepressants.
Given these obstacles, pharmacological strategies that mimic the effects of endurance exercise on skeletal muscle and its secreted factors may represent a novel therapeutic avenue. The authors propose that targeted exercise mimetics warrant further preclinical and clinical investigation as potential adjuncts in the treatment of depression.